Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Sci Adv ; 6(11): eaax7515, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32195339

RESUMO

Many pathogens produce virulence factors that are specific toward their natural host. Clinically relevant methicillin-resistant Staphylococcus aureus (MRSA) isolates are highly adapted to humans and produce an array of human-specific virulence factors. One such factor is LukAB, a recently identified pore-forming toxin that targets human phagocytes by binding to the integrin component CD11b. LukAB exhibits strong tropism toward human, but not murine, CD11b. Here, phylogenetics and biochemical studies lead to the identification of an 11-residue domain required for the specificity of LukAB toward human CD11b, which is sufficient to render murine CD11b compatible with toxin binding. CRISPR-mediated gene editing was used to replace this domain, resulting in a "humanized" mouse. In vivo studies revealed that the humanized mice exhibit enhanced susceptibility to MRSA bloodstream infection, a phenotype mediated by LukAB. Thus, these studies establish LukAB as an important toxin for MRSA bacteremia and describe a new mouse model to study MRSA pathobiology.


Assuntos
Proteínas de Bactérias/metabolismo , Toxinas Bacterianas/metabolismo , Antígeno CD11b/metabolismo , Leucocidinas/metabolismo , Staphylococcus aureus Resistente à Meticilina/metabolismo , Infecções Estafilocócicas/metabolismo , Fatores de Virulência/metabolismo , Animais , Proteínas de Bactérias/genética , Toxinas Bacterianas/genética , Antígeno CD11b/genética , Células HL-60 , Humanos , Leucocidinas/genética , Staphylococcus aureus Resistente à Meticilina/genética , Camundongos , Camundongos Transgênicos , Infecções Estafilocócicas/genética , Fatores de Virulência/genética
3.
Postgrad Med J ; 53(617): 159-61, 1977 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-870893

RESUMO

A new-born baby with Beckwith's syndrome had severe hypoglycaemia, and was treated with glucagon and prednisone. Treatment was stopped at 1 month of age and his blood glucose levels were satisfactory for the ensuing 6 weeks. However, at 10 weeks of age, he had a hypoglycaemic convulsion and required large doses of diazoxide and prednisone for the next 2 months to maintain the blood glucose above 40 mg/100 ml. Insulin excretion was raised until he was 4 months old. Cases of Beckwith's syndrome which develop hypoglycaemia, should be treated with diazoxide and corticosteroids until insulin excretion is normal.


Assuntos
Anormalidades Múltiplas , Hipoglicemia/etiologia , Doenças do Recém-Nascido/tratamento farmacológico , Corticosteroides/uso terapêutico , Diazóxido/uso terapêutico , Hérnia Umbilical/congênito , Humanos , Lactente , Recém-Nascido , Macroglossia , Masculino , Síndrome
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA